Six-Month Injection Shows Promising Results as New HIV Prevention Method
A new HIV prevention method, delivered via a six-month injection, has demonstrated remarkable effectiveness in clinical trials. Lenacapavir, the long-acting antiretroviral drug, proved to be significantly more effective than daily oral PrEP (pre-exposure prophylaxis), according to research published in the esteemed New England Journal of Medicine.
The international study, led by researchers from Emory University and Grady Health System, involved over 2,000 participants. Only two individuals receiving Lenacapavir contracted HIV, compared to nine cases among those taking daily PrEP. This translates to an overall effectiveness rate of 96% for Lenacapavir, highlighting its potential as a game-changer in HIV prevention.
“Lenacapavir’s near 100% effectiveness is remarkable, especially for those who cannot take the drug every day or who have limited medical resources,” said Dr. Colleen Kelley, professor at Emory University School of Medicine and the study’s lead investigator.
The trial enlisted diverse participants from countries including Peru, Brazil, Argentina, Mexico, South Africa, Thailand, and the United States, deliberately targeting communities disproportionately impacted by HIV. This focus stemmed from the recognition that many individuals in these groups struggle with adhering to daily medication regimens, underscoring the urgent need for more convenient and accessible alternatives.
The alarming statistic that over half of new HIV cases in the United States in 2022 were among cisgender gay men, with 70% being African-American or Hispanic, further emphasizes the critical need for flexible prevention strategies.
With the successful completion of the Phase III clinical trial, marke
ting applications for Lenacapavir have been submitted to the U.S. Food and Drug Administration. Researchers are hopeful for approval by 2025, potentially offering a groundbreaking solution for individuals who face challenges with traditional daily medication.
Dr. Carlos del Rio, head of the Department of Internal Medicine at Emory University, highlighted the significance of this breakthrough: “Long-acting antiretroviral drugs add new tools to HIV prevention. HIV infections worldwide Increase the number of HIV infection.”
Lenacapavir’s impressive effectiveness, coupled with its convenient administration, holds immense promise for reducing HIV transmission rates and transforming HIV prevention efforts globally.
An HIV prevention injection (Lenacapavir) is given every six months, and clinical trials have shown it to be more effective than oral PrEP. (Associated Press)
2024-12-01 05:14:00
#day #AIDS #prevention #injections #effective #year #Free #Health #Network
## Could a Six-Month Injection Be the Future of HIV Prevention?
**Experts Discuss Groundbreaking Results from Lenacapavir Trials**
A new long-acting HIV prevention method,delivered through a simple injection every six months,has shown remarkable promise in clinical trials,potentially revolutionizing HIV prevention strategies globally. Lenacapavir, an antiretroviral drug, proved significantly more effective than daily oral PrEP (pre-exposure prophylaxis) in a large international study published in the New England Journal of Medicine.
To delve deeper into the implications of these findings,we spoke with **Dr. Colleen Kelley**, Professor at Emory University School of Medicine and lead investigator of the Lenacapavir trial, and **dr. Carlos del Rio**, Head of the Department of Internal Medicine at Emory University, to discuss the potential impact of Lenacapavir and its role in the fight against HIV.
### Cutting-Edge Results
**Dr. Kelley**, can you elaborate on the key findings of the Lenacapavir trial and what makes them so significant?
“the trial demonstrated that Lenacapavir achieved a near 100% effectiveness rate in preventing HIV transmission, compared to 90% for daily oral PrEP. This is a remarkable achievement, particularly considering the diverse populations we involved – from Peru to South Africa to the US. These results are incredibly encouraging, especially for individuals who struggle with adhering to daily medication regimens.”
### addressing Accessibility Challenges
**dr. Del Rio**,how do you see Lenacapavir addressing the accessibility challenges faced by many communities disproportionately affected by HIV?
“ Access to healthcare and affordable,convenient prevention options are notably lacking for certain communities,contributing to the disparities we see in HIV rates. Lenacapavir’s long-acting nature and simple governance could be truly transformative for these populations, providing a much-needed and user-friendly option.”
### Hope for the Future
**Dr. Kelley**, looking forward, what are the next steps for bringing Lenacapavir to those who need it?
“ We’ve submitted marketing applications to the FDA, and we are hopeful for approval by 2025.If approved, Lenacapavir could offer a groundbreaking solution for individuals who face challenges with daily medications, paving the way for more accessible and effective HIV prevention worldwide.”
**Dr.Del Rio**, what is your overall assessment of Lenacapavir’s potential impact on the global fight against HIV?
“Lenacapavir represents a significant advancement in HIV prevention.
The combination of its high efficacy and convenient administration holds immense promise for reducing transmission rates, particularly among vulnerable populations. This could be a game-changer in our global efforts to end the HIV epidemic.”
### Empowering Individuals and Communities
Lenacapavir offers a beacon of hope in the ongoing battle against HIV. by providing a more accessible and effective prevention option, it empowers individuals and communities to take control of their sexual health.
**What are your thoughts on the future of HIV prevention? Share your comments below.**
***
For more facts on HIV prevention methods and support resources, visit:
[Link to relevant association website]
[Link to another relevant article on your website]
